FDA approves new single tablet HIV treatment

The FDA yesterday approved Bristol-Myers Squibb’s and Gilead Sciences Atripla, the first ever once-a-day single tablet regiment to treat HIV as a stand-alone therapy or in combination with other retrovirals. It is the first AIDS treatment to mix drugs made by different manufacturers. Atripla combines Bristol-Myers Squibb’s Sustiva, and Gilead’s Truvada and will be available in the US within seven business days, the companies said. The two companies established their joint venture to develop and commercialize Atripla in December 2004.s The FDA cleared the Atripla in less than three months as part of a push to introduce treatments that combine already-approved HIV drugs.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.